{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:05:30Z","timestamp":1782486330238,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Soluble guanylate cyclase (sGC) modulation has been scrutinized in several disease states including heart failure (HF). Recently, it was shown that an sGC modulator improved HF-related hospitalization significantly, though, there was no benefit related to mortality. Herein, a comprehensive meta-analysis of randomized controlled trials (RCTs) for sGC modulation in HF patients was provided in agreement with the PRISMA statement. A total of 10 RCTs yielding 12 papers were included. There were 7526 patients with heart failure of each phenotype, 4253 in the sGC modulator group and 3273 in the placebo group. Use of sGC modulators in HF patients yielded no significant difference in the risk of all-cause mortality compared to placebo (RR\u2009=\u20090.97, 95% CI 0.88\u20131.08, <jats:italic>p<\/jats:italic>\u2009=\u20090.62). The use of sGC modulators was associated with a trend toward a considerable but non-significant increase in the incidence of SAEs (RR\u2009=\u20091.10, 95% CI 0.99\u20131.22, <jats:italic>p<\/jats:italic>\u2009=\u20090.07), as well as an increased incidence of hypotension and anemia. There was an overall neutral effect of sGC modulation on NT-proBNP levels, 6MWD and mortality, at a cost of slight increase in hypotension and anemia. Of note, the improvement in EQ-5D-based quality of life was significant. Hence, the benefit seems to be driven by distinctive domains of quality of life.<\/jats:p>","DOI":"10.1038\/s41598-024-57695-7","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T07:01:39Z","timestamp":1711263699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy and safety of soluble guanylate cyclase modulation in patients with heart failure: a comprehensive meta-analysis of randomized controlled trials"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0492-5129","authenticated-orcid":false,"given":"Mehmet Emin","family":"Arayici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-5046","authenticated-orcid":false,"given":"Hakan","family":"Gunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8503-061X","authenticated-orcid":false,"given":"Hulya","family":"Ellidokuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-8628","authenticated-orcid":false,"given":"Mehmet Birhan","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,24]]},"reference":[{"key":"57695_CR1","first-page":"303","volume":"20","author":"H Strijdom","year":"2009","unstructured":"Strijdom, H., Chamane, N. & Lochner, A. Nitric oxide in the cardiovascular system: A simple molecule with complex actions. Cardiovasc. J. Afr. 20, 303\u2013310 (2009).","journal-title":"Cardiovasc. J. Afr."},{"key":"57695_CR2","doi-asserted-by":"publisher","first-page":"8948","DOI":"10.1021\/jm400539d","volume":"56","author":"M von Wantoch Rekowski","year":"2013","unstructured":"von Wantoch Rekowski, M. et al. Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics. J. Med. Chem. 56, 8948\u20138952 (2013).","journal-title":"J. Med. Chem."},{"key":"57695_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11897-010-0045-1","volume":"8","author":"V Mitrovic","year":"2011","unstructured":"Mitrovic, V., Jovanovic, A. & Lehinant, S. Soluble guanylate cyclase modulators in heart failure. Curr. Heart Fail. Rep. 8, 38\u201344 (2011).","journal-title":"Curr. Heart Fail. Rep."},{"key":"57695_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15698","author":"P Sandner","year":"2021","unstructured":"Sandner, P. et al. Soluble GC stimulators and activators: Past, present and future. Br. J. Pharmacol. https:\/\/doi.org\/10.1111\/bph.15698 (2021).","journal-title":"Br. J. Pharmacol."},{"key":"57695_CR5","doi-asserted-by":"publisher","first-page":"e12709","DOI":"10.1097\/MD.0000000000012709","volume":"97","author":"X Zheng","year":"2018","unstructured":"Zheng, X., Zheng, W., Xiong, B. & Huang, J. The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. Medicine Baltimore. 97, e12709 (2018).","journal-title":"Medicine Baltimore."},{"key":"57695_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4330\/wjc.v12.i10.501","volume":"12","author":"W Ullah","year":"2020","unstructured":"Ullah, W. et al. Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. World J. Cardiol. 12, 501\u2013511 (2020).","journal-title":"World J. Cardiol."},{"key":"57695_CR7","first-page":"488","volume":"76","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. Pharmazie 76, 488\u2013493 (2021).","journal-title":"Pharmazie"},{"key":"57695_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","journal-title":"BMJ."},{"key":"57695_CR9","doi-asserted-by":"crossref","unstructured":"Ghimire, S., Kyung, E., Kang, W. & Kim, E. Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals. Trials 13, 77 (2012).","DOI":"10.1186\/1745-6215-13-77"},{"key":"57695_CR10","doi-asserted-by":"publisher","unstructured":"Higgins, J. P. T. Cochrane Handbook for Systematic Reviews of Interventions. (Wiley-Blackwell, 2019). https:\/\/doi.org\/10.1002\/9781119536604.","DOI":"10.1002\/9781119536604"},{"key":"57695_CR11","doi-asserted-by":"crossref","unstructured":"Wan, X., Wang, W., Liu, J. & Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.\u00a0BMC Med. Res. Methodol.\u00a014, 135 (2014).","DOI":"10.1186\/1471-2288-14-135"},{"key":"57695_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634 (1997).","journal-title":"BMJ"},{"key":"57695_CR13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088\u20131101 (1994).","journal-title":"Biometrics"},{"key":"57695_CR14","unstructured":"RevMan.\u00a0Cochrane.org\u00a0https:\/\/training.cochrane.org\/online-learning\/core-software\/revman."},{"key":"57695_CR15","unstructured":"ProMeta 3 \u2013 IDoStatistics.\u00a0Idostatistics.com\u00a0https:\/\/idostatistics.com\/prometa3\/."},{"key":"57695_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","volume":"14","author":"M Gheorghiade","year":"2012","unstructured":"Gheorghiade, M. et al. Cinaciguat, a soluble guanylate cyclase activator: Results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur. J. Heart Fail. 14, 1056\u20131066 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"57695_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","volume":"34","author":"E Erdmann","year":"2013","unstructured":"Erdmann, E. et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur. Heart J. 34, 57\u201367 (2013).","journal-title":"Eur. Heart J."},{"key":"57695_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","volume":"128","author":"D Bonderman","year":"2013","unstructured":"Bonderman, D. et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128, 502\u2013511 (2013).","journal-title":"Circulation"},{"key":"57695_CR19","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1378\/chest.14-0106","volume":"146","author":"D Bonderman","year":"2014","unstructured":"Bonderman, D. et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1). Chest 146, 1274\u20131285 (2014).","journal-title":"Chest"},{"key":"57695_CR20","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade, M. et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA 314, 2251 (2015).","journal-title":"JAMA"},{"key":"57695_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske, B. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur. Heart J. 38, 1119\u20131127 (2017).","journal-title":"Eur. Heart J."},{"key":"57695_CR22","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W. et al. Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 382, 1883\u20131893 (2020).","journal-title":"N. Engl. J. Med."},{"key":"57695_CR23","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1001\/jama.2020.16641","volume":"324","author":"JE Udelson","year":"2020","unstructured":"Udelson, J. E. et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: The CAPACITY HFpEF randomized clinical trial. JAMA 324, 1522 (2020).","journal-title":"JAMA"},{"key":"57695_CR24","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","volume":"324","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W. et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial. JAMA 324, 1512 (2020).","journal-title":"JAMA"},{"key":"57695_CR25","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","volume":"43","author":"TM Dachs","year":"2022","unstructured":"Dachs, T. M. et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: The haemoDYNAMIC trial. Eur. Heart J. 43, 3402\u20133413 (2022).","journal-title":"Eur. Heart J."},{"key":"57695_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jchf.2022.04.015","volume":"10","author":"PW Armstrong","year":"2022","unstructured":"Armstrong, P. W. et al. Sequential evaluation of NT-proBNP in heart failure. JACC Heart Fail. 10, 677\u2013688 (2022).","journal-title":"JACC Heart Fail."},{"key":"57695_CR27","doi-asserted-by":"crossref","unstructured":"Butler, J.\u00a0et al.\u00a0Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.\u00a0Circ. Heart Fail.\u00a015, e009337 (2022).","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337"},{"key":"57695_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","volume":"122","author":"EJ Tsai","year":"2009","unstructured":"Tsai, E. J. & Kass, D. A. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol. Ther. 122, 216\u2013238 (2009).","journal-title":"Pharmacol. Ther."},{"key":"57695_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ahj.2021.07.003","volume":"241","author":"N Moghaddam","year":"2021","unstructured":"Moghaddam, N., Malhi, N. & Toma, M. Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials. Am. Heart J. 241, 74\u201382 (2021).","journal-title":"Am. Heart J."},{"key":"57695_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.100924","volume":"47","author":"RA Thakker","year":"2022","unstructured":"Thakker, R. A. et al. Outcomes with sGC therapy in patients with HFpEF: A meta-analysis of prior trials. Curr. Probl. Cardiol. 47, 100924 (2022).","journal-title":"Curr. Probl. Cardiol."},{"key":"57695_CR31","doi-asserted-by":"crossref","unstructured":"Thomas, M.\u00a0et al.\u00a0Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure.\u00a0Eur. Heart J. Qual. Care Clin. Outcomes\u00a07, 388\u2013396 (2021).","DOI":"10.1093\/ehjqcco\/qcab014"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57695-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T07:01:47Z","timestamp":1711263707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57695-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["57695"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-57695-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,24]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.E.A., H.G., and H.E. declare that they have no conflicts of interest to be disclosed. M.B.Y. has received an institutional research fee from Bayer Healthcare Pharmaceuticals, Amgen, Novartis, Dalcor Pharmaceuticals, Novo Nordisk, Astra Zeneca, and Boehringer Ingelheim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6987"}}